Kestra Private Wealth Services LLC Has $471,000 Stake in Exact Sciences Co. (NASDAQ:EXAS)

Kestra Private Wealth Services LLC boosted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 22.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,387 shares of the medical research company’s stock after purchasing an additional 1,564 shares during the period. Kestra Private Wealth Services LLC’s holdings in Exact Sciences were worth $471,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in EXAS. Groupama Asset Managment acquired a new stake in shares of Exact Sciences in the 3rd quarter valued at $821,000. ArrowMark Colorado Holdings LLC bought a new position in Exact Sciences during the third quarter worth about $28,608,000. Iron Triangle Partners LP bought a new stake in shares of Exact Sciences in the third quarter valued at about $27,239,000. Erste Asset Management GmbH bought a new stake in shares of Exact Sciences in the third quarter valued at about $26,546,000. Finally, Bellevue Group AG lifted its holdings in shares of Exact Sciences by 25.1% in the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock valued at $98,738,000 after purchasing an additional 290,585 shares in the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $49.31 on Friday. The company has a market capitalization of $9.13 billion, a price-to-earnings ratio of -42.14 and a beta of 1.24. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The stock has a fifty day simple moving average of $56.15 and a 200 day simple moving average of $60.18. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72.

Wall Street Analysts Forecast Growth

EXAS has been the topic of several analyst reports. BTIG Research upped their target price on Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Evercore ISI lowered their price target on Exact Sciences from $80.00 to $60.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Barclays began coverage on Exact Sciences in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $70.00 target price on the stock. Stifel Nicolaus decreased their target price on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group decreased their target price on Exact Sciences from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.